These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 8765034)

  • 21. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
    Brooks JM; Murray RJ; Thomas WA; Kurilla MG; Rickinson AB
    J Exp Med; 1993 Sep; 178(3):879-87. PubMed ID: 7688791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cross-recognition of a mouse H-2-peptide complex by human HLA-restricted cytotoxic T cells.
    Murray RJ; Brooks JM; Rickinson AB; Rowe M
    Eur J Immunol; 1990 Mar; 20(3):659-64. PubMed ID: 1690661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
    Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
    J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.
    Lee SP; Wallace LE; Mackett M; Arrand JR; Searle PF; Rowe M; Rickinson AB
    Int Immunol; 1993 May; 5(5):451-60. PubMed ID: 8391306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells.
    Khanna R; Busson P; Burrows SR; Raffoux C; Moss DJ; Nicholls JM; Cooper L
    Cancer Res; 1998 Jan; 58(2):310-4. PubMed ID: 9443410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
    J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.
    Pepperl S; Benninger-Döring G; Modrow S; Wolf H; Jilg W
    J Virol; 1998 Nov; 72(11):8644-9. PubMed ID: 9765404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presentation of viral antigens restricted by H-2Kb, Db or Kd in proteasome subunit LMP2- and LMP7-deficient cells.
    Zhou X; Momburg F; Liu T; Abdel Motal UM; Jondal M; Hämmerling GJ; Ljunggren HG
    Eur J Immunol; 1994 Aug; 24(8):1863-8. PubMed ID: 8056044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
    Khanna R; Burrows SR; Suhrbier A; Jacob CA; Griffin H; Misko IS; Sculley TB; Rowe M; Rickinson AB; Moss DJ
    J Immunol; 1993 Jun; 150(11):5154-62. PubMed ID: 7684421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A viral, transporter associated with antigen processing (TAP)-independent, high affinity ligand with alternative interactions endogenously presented by the nonclassical human leukocyte antigen E class I molecule.
    Lorente E; Infantes S; Abia D; Barnea E; Beer I; García R; Lasala F; Jiménez M; Mir C; Morreale A; Admon A; López D
    J Biol Chem; 2012 Oct; 287(42):34895-34903. PubMed ID: 22927436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2.
    Lautscham G; Haigh T; Mayrhofer S; Taylor G; Croom-Carter D; Leese A; Gadola S; Cerundolo V; Rickinson A; Blake N
    J Virol; 2003 Feb; 77(4):2757-61. PubMed ID: 12552018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
    Levitskaya J; Coram M; Levitsky V; Imreh S; Steigerwald-Mullen PM; Klein G; Kurilla MG; Masucci MG
    Nature; 1995 Jun; 375(6533):685-8. PubMed ID: 7540727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An HLA-A2-restricted T-cell epitope mapped to the BNLF2a immune evasion protein of Epstein-Barr virus that inhibits TAP.
    Bell MJ; Abbott RJ; Croft NP; Hislop AD; Burrows SR
    J Virol; 2009 Mar; 83(6):2783-8. PubMed ID: 19129449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
    Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
    Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.
    Kienzle N; Sculley TB; Poulsen L; Buck M; Cross S; Raab-Traub N; Khanna R
    J Virol; 1998 Aug; 72(8):6614-20. PubMed ID: 9658107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
    Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
    Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carrier-mediated uptake and presentation of a major histocompatibility complex class I-restricted peptide.
    Brander C; Wyss-Coray T; Mauri D; Bettens F; Pichler WJ
    Eur J Immunol; 1993 Dec; 23(12):3217-23. PubMed ID: 8258336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.